Browsing by Author "Buccilli, Kate"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis
    (2024) Wannan, Cassandra M. J.; Nelson, Barnaby; Addington, Jean; Allott, Kelly; Anticevic, Alan; Arango, Celso; Baker, Justin T.; Bearden, Carrie E.; Billah, Tashrif; Bouix, Sylvain; Broome, Matthew R.; Buccilli, Kate; Cadenhead, Kristin S.; Calkins, Monica E.; Cannon, Tyrone D.; Cecci, Guillermo; Chen, Eric Yu Hai; Cho, Kang Ik K; Choi, Jimmy; Clark, Scott R.; Coleman, Michael J.; Conus, Philippe; Cheryl M Corcoran, Cheryl M.; Cornblatt, Barbara; Diaz-Caneja, Covadonga M.; Dwyer, Dominic; Ebdrup, Bjorn H.; Ellman, Lauren M.; Fusar-Poli, Paolo; Galindo, Liliana; Gaspar, Pablo A.; Gerber, Carla; Birkedal Glenthøj, Louise; Glynn, Robert; Harms , Michael; Horton, Leslie E.; Kahn, René S.; Kambeitz-Ilankovic, Joseph; Kane, John M.; Castillo-Passi, Rolando
    This article describes the rationale, aims, and methodology of the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ). This is the largest international collaboration to date that will develop algorithms to predict trajectories and outcomes of individuals at clinical high risk (CHR) for psychosis and to advance the development and use of novel pharmacological interventions for CHR individuals. We present a description of the participating research networks and the data processing analysis and coordination center, their processes for data harmonization across 43 sites from 13 participating countries (recruitment across North America, Australia, Europe, Asia, and South America), data flow and quality assessment processes, data analyses, and the transfer of data to the National Institute of Mental Health (NIMH) Data Archive (NDA) for use by the research community. In an expected sample of approximately 2000 CHR individuals and 640 matched healthy controls, AMP SCZ will collect clinical, environmental, and cognitive data along with multimodal biomarkers, including neuroimaging, electrophysiology, fluid biospecimens, speech and facial expression samples, novel measures derived from digital health technologies including smartphone-based daily surveys, and passive sensing as well as actigraphy. The study will investigate a range of clinical outcomes over a 2-year period, including transition to psychosis, remission or persistence of CHR status, attenuated positive symptoms, persistent negative symptoms, mood and anxiety symptoms, and psychosocial functioning. The global reach of AMP SCZ and its harmonized innovative methods promise to catalyze the development of new treatments to address critical unmet clinical and public health needs in CHR
  • Thumbnail Image
    Publication
    Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample
    (2025) Allott, Kelly; Yassin, Walid; Alameda, Luis; Billah, Tashrif; Borders, Owen; Buccilli, Kate; Carrión, Ricardo E.; Castillo-Passi, Rolando I.; Cho, Kang Ik K.; Chin, Kota; Coleman, Michael J.; Colton, Beau-Luke; Corral, Sebastián; Dwyer, Dominic; Gundersen, Kristina Ballestad; Gur, Ruben C.; Hoftman, Gil D.; Jacobs, Grace R.; Kelly, Sinead; Lewandowski, Kathryn E.; Marcy, Patricia J.; Matneja, Priya; McLaughlin, Danielle; Nunez, Angela R.; Parsa, Setari; Penzel, Nora; Ray, Susan; Reinen, Jenna M.; Ruparel, Kosha; Sand, Michael S.; Santorelli, Gennarina; Seitz-Holland, Johanna; Spark, Jessica; Tamayo, Zailyn; Thompson, Andrew; Tod, Sophie; Wannan, Cassandra M. J.; Wickham, Alana; Wood, Stephen J.; Zoupou, Eirini
    Cognitive impairment occurs at higher rates in individuals at clinical high risk (CHR) for psychosis relative to healthy peers, and it contributes unique variance to multivariate prediction models of transition to psychosis. Such impairment is considered a core biomarker of schizophrenia. Thus, cognition is a key domain measured in the Accelerating Medicines Partnership® program for Schizophrenia (AMP SCZ initiative). The aim of this paper is to describe the rationale, processes, considerations, and final harmonization of the cognitive battery used in AMP SCZ across the two data collection networks. This battery comprises tests of general intellect and specific cognitive domains. We estimate premorbid intelligence at baseline and measure current intelligence at baseline and 2 years. Eight tests from the Penn Computerized Neurocognitive Battery (PennCNB), which measure verbal learning and memory, sensorimotor ability, attention, emotion recognition, working memory, processing speed, verbal memory, visual memory, and motor speed are administered repeatedly at baseline, and four follow-up timepoints over 2 years. Watch Dr. Kelly Allott and Dr. William S. Stone discuss their work and this article: https://vimeo.com/1023396087.

Implementado por OpenGeek Services